Monday, July 6, 2026
← Back to archivePolicy
Policy•STAT News•Jul 6, 2026
Opinion: The smart way to regulate the peptide boom
background ▾
- •FDA's PCAC meeting (July 23-24) will consider whether to restore peptides to the 503A pharmacy compounding eligibility list, potentially reshaping regulatory access to wellness peptides currently sold in gray/black markets
- •The argument proposes a clinician-supervised compounding framework as a middle path between prohibition and unrestricted access, framed as a harm-reduction strategy to capture real-world safety data while reducing black-market use
- •Watch for the FDA's July PCAC decision and any follow-up guidance before February 2027; this could signal a broader regulatory pivot on how the agency handles consumer-driven demand for unapproved peptide compounds
semaglutideGLP-1 agonistsinsulin
→ Read original articlePolicy•STAT News•Jul 6, 2026
Opinion: Stopping doctors from ordering unnecessary diagnostic tests requires a structural fix
background ▾
- •Diagnostic stewardship—structural, systems-level interventions to modify test ordering—is more effective than physician education alone at reducing inappropriate testing and unnecessary treatment
- •The Michigan hospital system demonstrated that embedding clinical decision support directly into EMR workflows and laboratory protocols can reduce inappropriate antibiotic prescribing for asymptomatic bacteriuria by approximately 41%, with broad applicability across molecular diagnostics and imaging modalities
- •Watch for healthcare policy initiatives, payer mandates, or CMS quality measures that incorporate diagnostic stewardship principles into hospital quality standards and reimbursement models
Policy•STAT News•Jul 6, 2026
What does content creation do to mental health?
background ▾
Policy•Endpoints News•Jul 4, 2026
Anthropic launches Claude Science; House China panel probes trial sites; and more
background ▾
- •House China panel is investigating clinical trial sites, indicating potential regulatory scrutiny of trial operations or foreign involvement
Policy•KFF•Jul 1, 2026
Medical Frailty and Medicaid Work Requirements: Challenges for People with HIV
background ▾
- •The CMS two-part medical frailty test (condition + functional impairment) is more restrictive than states anticipated and contradicts early state implementations that assumed diagnosis-alone exclusions would suffice, creating immediate legal and implementation uncertainty.
- •Medicaid expansion is the dominant coverage pathway for people with HIV (60% of eligible adults in expansion states), making this policy change a direct threat to treatment continuity and HIV prevention/management efforts for a highly vulnerable population.
- •Outcome of the Massachusetts District Court challenge will determine whether the two-part functional test stands or reverts to broader condition-based exclusions; ruling expected to reshape state implementation timelines and coverage stability for people with HIV.
Market Access
Market Access•Fierce Biotech•Jul 6, 2026
Novartis to pay $1.1B upfront for UK biotech Myricx to expand the pharma's ADC pipeline
background ▾
- •Novartis is shifting oncology strategy to include ADCs as a core pillar, acquiring a novel-payload platform to compete in a space dominated by TOPO-1 inhibitor ADCs
- •Myricx's NMTi payloads target senescent cells and have shown preclinical parity or superiority to TOPO-1 ADCs in solid tumors, but clinical validation against approved competitors (Enhertu, ifinatamab) remains the key de-risking event
- •Watch for clinical readouts from Myricx's HER2 and B7-H3 NMTi-ADC programs; success could unlock broad platform expansion across multiple targets and reshape ADC payload preferences
NovartisMyricx BioAstraZenecaEnhertuPadcevifinatamab deruxtecan
→ Read original articleMarket Access•Fierce Biotech•Jul 3, 2026
United Therapeutics pays $140M for thymic cell therapy startup
background ▾
- •United Therapeutics gains exclusive access to a potentially superior thymic regeneration platform (THY-100) with greater scalability than the incumbent Rethymic, positioning it to capture the congenital athymia market and potential future indications.
- •All 49 children with untreated congenital athymia died by age 3 in the natural history cohort, establishing clear clinical need; Rethymic achieved 77% one-year survival and 94% long-term survival, setting a high bar for THY-100 efficacy.
- •Watch for: THY-100 IND filing and first-in-human trial initiation (likely 2024–2025); clinical data on neo-thymus formation and T-cell reconstitution in humans; potential expansion into transplant tolerance, immune-mediated disease, and aging applications if proof-of-concept is demonstrated.
United TherapeuticsThymmune TherapeuticsSumitomo PharmaTHY-100Rethymic
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jul 3, 2026
AstraZeneca pens $1.7B kidney drug discovery pact with go-to Chinese partner CSPC
background ▾
- •AstraZeneca continues aggressive expansion of its kidney disease portfolio through strategic partnerships, building on Farxiga's blockbuster performance ($2.2B Q1 sales) and addressing a significant unmet need in renal indications
- •CSPC's siRNA delivery platform for extrahepatic organs fills a critical gap in nucleic acid therapeutics, overcoming historical liver-targeting limitations and positioning both companies to compete in growing RNA medicine markets
- •Monitor clinical trial initiation timelines for the two undisclosed renal targets and watch for CSPC's ability to replicate success from its obesity partnership ($18.5B deal value) in a different therapeutic area
AstraZenecaCSPC PharmaceuticalFarxigaLokelma
→ Read original article